The case for & against
Bull & Bear analysis
Bullish
Eli Lilly and Company (NYSE: LLY) is a leading global pharmaceutical company, primarily recognized for its innovative medications across various therapeutic areas, particularly in diabetes and oncology. As a major player in the competitive healthcare landscape, Lilly has established a strong presence with its GLP-1 drugs including Mounjaro and Zepbound, which are driving substantial revenue growth. The company is also actively pursuing acquisitions to diversify its portfolio, signaling a strategic approach to sustaining long-term growth as the industry evolves.
Bull says
- ↑Analysts forecast EPS of $35.93 in FY26 (≈+48.4% growth).
- ↑Mounjaro and Zepbound sales projected to exceed $100B by 2030.
- ↑Revenue rose from $28.3B in FY21 to $65.2B in FY25 (+48% YoY).
- ↑Strategic acquisitions (e.g., Merida Biosciences) diversify pipeline.
- ↑Average earnings surprise of +21.3% underpins momentum.
- ↑Strong earnings yield and positive analyst revisions boost valuation case.
Bear says
- ↓Reliance on GLP-1 drugs could face market saturation, slowing revenue.
- ↓Shares down ~10.5% from 52-week high reflects weak sentiment.
- ↓Acquisition integration complexities may strain execution and dilute focus.
- ↓Current valuations may overlook sector risks, risking multiple compression.
- ↓High volatility and moderate future sales growth could pressure margins.
- ↓Factor exposure shows elevated volatility, limiting downside protection.